An interventional study of somofilcon A lens and stenfilcon A lens in Hyperopia and Myopia, sponsored by CooperVision International Limited (CVIL). Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment
The aim of this study is to assess contact lens performance and acceptance.
The objective of this study is to assess the initial performance and acceptance of a range of contact lenses in habitual soft contact lens wearers.
156 studies on the registry are indexed under Hyperopia; 20 are open to participants now.
This study's enrollment of 36 is below the median of 60 across 125 interventional studies indexed under Hyperopia.
Browse Hyperopia studies →CooperVision International Limited (CVIL) is the lead sponsor of 138 studies on the registry; 6 are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 66 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: somofilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: stenfilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: fanfilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: comfilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: verofilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: serafilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: lehfilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: delefilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: senofilcon A daily disposable lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: senofilcon A with blue light technology lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: senofilcon A bi-weekly lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: samfilcon A lens
Participants will wear thirteen different types of study contact lenses, in a randomized order of testing for the thirteen study contact lens types.
Device: kalilfilcon A lens
Participants will be randomized to wear somofilcon A soft contact lens for 10 hours.
Participants will be randomized to wear stenfilcon A soft contact lens for 10 hours.
Participants will be randomized to wear fanfilcon A soft contact lens for 10 hours.
Participants will be randomized to wear comfilcon A soft contact lens for 10 hours.
Participants will be randomized to wear verofilcon A soft contact lens for 10 hours.
Participants will be randomized to wear serafilcon A soft contact lens for 10 hours.
Participants will be randomized to wear lehfilcon A soft contact lens for 10 hours.
Participants will be randomized to wear delefilcon A soft contact lens for 10 hours.
Participants will be randomized to wear senofilcon A soft contact lens for 10 hours.
Participants will be randomized to wear senofilcon A soft contact lens for 10 hours.
Participants will be randomized to wear senofilcon A soft contact lens for 10 hours.
Participants will be randomized to wear samfilcon A soft contact lens for 10 hours.
Participants will be randomized to wear kalifilcon A soft contact lens for 10 hours.
High contrast, high luminance binocular distance visual acuity
High contrast, high luminance binocular distance visual acuity (logMAR) will be measured at 10-hour visit.
Time frame: At the end of 10 hours of daily wear at dispensing
Ran from Nov 2025 to primary completion in Dec 2025, 1 month.
Of 36 industry-sponsored interventional studies with no phase under Hyperopia, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 1 month is below that.
Counting every sponsor, half of 54 studies reached it within 10 months; a quarter within 4 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CooperVision International Limited (CVIL) →